[Current state of neoadjuvant therapy of soft tissue sarcoma].
The treatment of soft tissue sarcoma is clinically challenging. Referral to an experienced center with an interdisciplinary team is strongly recommended. Neoadjuvant therapy, including irradiation and chemotherapy, has been applied to improve local control rates, eradicate micrometastases and assess chemosensitivity. However, the role of neoadjuvant therapy remains controversial, especially for systemic therapy, as the only available randomized trial failed to prove a benefit for survival. Nevertheless, on the basis of the current body of literature, neoadjuvant therapy can be considered on an individual basis for patients with high-risk tumors. Whenever possible, patients should be included in a clinical trial.
Klinik für Hand-, Plastische- und Rekonstruktive Chirurgie, Schwerbrandverletztenzentrum, Klinik für Plastische Chirurgie der Ruprecht-Karls-Universität Heidelberg, BG-Unfallklinik Ludwigshafen, Ludwig-Guttmann-Str. 13, 67071, Ludwigshafen, Deutschland. Marcus.Lehnhardt@bgu-ludwigshafen.de
M
M
Lehnhardt
T
T
Schmitt
M
M
Bischof
A
A
Daigeler
G
G
Egerer
D010478:Chemotherapy, Cancer, Regional Perfusion; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006801:Humans; D006979:Hyperthermia, Induced; D020360:Neoadjuvant Therapy; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D012186:Retroperitoneal Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D012509:Sarcoma / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery; D012983:Soft Tissue Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy* / Q000601:surgery